Dana-farber-cancer Institute Inc.

Millennium Pharmaceuticals Limited

Jennifer Richardson

Wayne A Marasco

Andrew W Shyjan

John Vassiliadis

Joseph G Sodroski

Maria Cristina Parolin

The invention concerns ubiquitin-conjugating enzyme-like protein (UBCLP) nucleic acid molecules, polypeptides, antibodies, and modulators. The invention also concerns screening assays which can be used to identify compounds useful for the treatment of prostate cancer and diagnostic assays which can be used to detect prostate cancer, and prognostic assays which can be used to monitor prostate cancer therapy.

UBCLP and uses thereof

The invention concerns the use of KIAA0101 nucleic acids and polypeptides in prostate cancer diagnostic and drug screening methods.

Diagnostic and screening methods employing KIAA0101

The present invention is related to vectors and methods for increasing the expression of a desired gene product. Preferably this invention is used with genes expressing proteins that are not well tolerated by mammalian cells or where high levels of expression are necessary. In certain preferred embodiments it can be used as part of a multi-tiered expression system and with methods of intracellularly targeting a molecule.

Expression vectors and methods of use

The present invention relates to a method by which one can target an undesired target molecule or target antigen, preferably an endogenous protein. The method comprises the intracellular expression of an antibody capable of binding to the target. A DNA sequence is delivered to a cell, the DNA sequence contains a sufficient number of nucleotides coding for the portion of an antibody capable of binding to the target operably linked to a promoter that will permit expression of the antibody in the cell(s) of interest. The antibody is then expressed intracellularly and binds to the target, thereby disrupting the target from its normal actions.

Growing community of inventors

Boston, MA, United States of America

Jennifer Richardson